Institute for Global Health Sciences.
Division of Prevention Science, University of California, San Francisco, California, USA.
AIDS. 2018 Sep 24;32(15):2179-2188. doi: 10.1097/QAD.0000000000001958.
OBJECTIVES/DESIGN: As antiretroviral therapy (ART) rapidly expands in sub-Saharan Africa using new efficient care models, data on costs of these approaches are lacking. We examined costs of a streamlined HIV care delivery model within a large HIV test-and-treat study in Uganda and Kenya.
We calculated observed per-person-per-year (ppy) costs of streamlined care in 17 health facilities in SEARCH Study intervention communities (NCT: 01864603) via micro-costing techniques, time-and-motion studies, staff interviews, and administrative records. Cost categories included salaries, ART, viral load testing, recurring goods/services, and fixed capital/facility costs. We then modeled costs under three increasingly efficient scale-up scenarios: lowest-cost ART, centralized viral load testing, and governmental healthcare worker salaries. We assessed the relationship between community-specific ART delivery costs, retention in care, and viral suppression.
Estimated streamlined HIV care delivery costs were $291/ppy. ART ($117/ppy for TDF/3TC/EFV [40%]) and viral load testing ($110/ppy for 2 tests/year [39%]) dominated costs versus salaries ($51/ppy), recurring costs ($5/ppy), and fixed costs ($7/ppy). Optimized ART scale-up with lowest-cost ART ($100/ppy), annual viral load testing ($24/ppy), and governmental healthcare salaries ($27/ppy), lowered streamlined care cost to $163/ppy. We found clinic-to-clinic heterogeneity in retention and viral suppression levels versus streamlined care delivery costs, but no correlation between cost and either retention or viral suppression.
In the SEARCH Study, streamlined HIV care delivery costs were similar to or lower than prior estimates despite including viral load testing; further optimizations could substantially reduce costs further. These data can inform global strategies for financing ART expansion to achieve UNAIDS 90-90-90 targets.
目的/设计:随着抗逆转录病毒疗法(ART)在撒哈拉以南非洲地区迅速扩展,采用了新的高效护理模式,因此缺乏这些方法的成本数据。我们研究了乌干达和肯尼亚的一项大型 HIV 检测和治疗研究中简化护理的成本。
我们通过微观成本技术、时间和动作研究、员工访谈和行政记录,计算了 SEARCH 研究干预社区内 17 个卫生机构中简化护理的人均每年(ppy)观察成本(NCT:01864603)。成本类别包括工资、ART、病毒载量检测、经常性商品/服务以及固定资本/设施成本。然后,我们根据三种效率不断提高的扩展方案对成本进行建模:最低成本的 ART、集中式病毒载量检测和政府医疗保健工作者的工资。我们评估了社区特定的 ART 提供成本、保留在护理中以及病毒抑制之间的关系。
估计简化的 HIV 护理成本为 291 美元/ppy。ART(TDF/3TC/EFV[40%]的 117 美元/ppy)和病毒载量检测(每年 2 次测试的 110 美元/ppy[39%])的成本高于工资(51 美元/ppy)、经常性成本(5 美元/ppy)和固定成本(7 美元/ppy)。通过使用最低成本的 ART(100 美元/ppy)、每年进行病毒载量检测(24 美元/ppy)和政府医疗保健工资(27 美元/ppy)进行优化的 ART 扩展,简化的护理成本降低至 163 美元/ppy。我们发现,保留率和病毒抑制水平与简化护理成本之间存在诊所间的异质性,但成本与保留率或病毒抑制之间没有相关性。
在 SEARCH 研究中,尽管包括病毒载量检测在内,简化的 HIV 护理成本与之前的估计相似或更低;进一步的优化可以进一步大幅降低成本。这些数据可以为实现 UNAIDS 90-90-90 目标的全球筹资策略提供信息。